• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: MS

MS highlights from EAN 2019

July 10, 2019  

HSCT vs. drug in RRMS: head-to-head study

June 19, 2019  

Switching therapies in MS – what is the evidence?

May 28, 2019  

AAN 2019 DAILY REPORT

May 9, 2019  

Europe restricts alemtuzumab use for MS

May 1, 2019  

Secondary-progressive MS: conceptual and practical challenges

April 17, 2019  

Siponimod receives FDA approval for SPMS

March 29, 2019  

Polypharmacy common in MS patients

March 13, 2019  

Benefits to early switching in MS: MSBase analysis

February 27, 2019  

Phase III trials in neurology – 2018 in review

January 24, 2019  
Previous
22
23
24
25
26
Next

Browse by Topic

  • MS (442)
  • EAN 2026 (2)
  • CLINICAL CASES (21)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • EPILEPSY (38)
  • AES 2025 (1)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Anti-CD20 therapy in MS: comparing efficacy and safety posted on July 21, 2026
  • Highlights of EAN 2026 – Part 1 posted on June 30, 2026
  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions